肝细胞癌降期至肝移植的肿瘤负荷是否存在上限?All-Comers方案分析
比较74例超出UCSF降期标准的All-Comers组与133例符合UCSF降期标准组肝细胞癌患者降期至米兰标准的意向性治疗结局。All-Comers组降期成功率64.8%低于UCSF-DS组84.2%(P<0.001),1年与3年脱落累积概率分别为53.5%和80.0%高于UCSF-DS组的25.0%和36.1%(P<0.0001),肝移植率13.5%低于59.0%(P<0.001),1年与5年意向性治疗生存率分别为77.4%和21.1%低于85.5%和56.0%(P<0.001)。
要点
- All-Comers组降期成功率64.8%,低于UCSF-DS组的84.2%(P<0.001)。
- All-Comers组1年与3年脱落累积概率分别为53.5%和80.0%,高于UCSF-DS组的25.0%和36.1%。
- All-Comers组肝移植率13.5%,低于UCSF-DS组的59.0%(P<0.001)。
核心结论
- All-Comers组降期后肝移植概率显著低于UCSF-DS组,意向性治疗生存率也更差。
- 作者认为肿瘤负荷存在上限,超过该上限后降期后成功肝移植成为不现实的目标。
研究设计与样本
- 比较All-Comers组74例与UCSF-DS组133例肝细胞癌患者降期治疗的意向性治疗结局。
主要发现
- 成功降期至米兰标准:All-Comers组64.8% vs UCSF-DS组84.2%(P<0.001)。
- 肿瘤数目与最大肿瘤直径之和与成功降期显著相关(HR 0.87,P<0.05)。
- 1年与3年脱落累积概率:All-Comers组53.5%和80.0% vs UCSF-DS组25.0%和36.1%(P<0.0001)。
- 预测脱落的因素包括肿瘤数目与最大肿瘤直径之和大于8(HR 1.79,P=0.049)以及Child B级和C级(HR 2.54,P=0.001)。
- 肝移植率:All-Comers组13.5% vs UCSF-DS组59.0%(P<0.001);1年与5年意向性治疗生存率:All-Comers组77.4%和21.1% vs UCSF-DS组85.5%和56.0%(P<0.001)。
关键数值与推荐
- UCSF降期标准:一个病灶>5 cm且≤8 cm;两至三个病灶各≤5 cm;或四至五个病灶各≤3 cm且总肿瘤直径≤8 cm。
- All-Comers定义为初始肿瘤负荷超出UCSF降期标准。
- All-Comers组10例接受肝移植的患者中3例出现肝细胞癌复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with hepatocellular carcinoma (HCC) within the University of California, San Francisco down-staging (UCSF-DS) criteria (one lesion > 5 cm and ≤ 8 cm; two to three lesions each ≤ 5 cm; or four to five lesions each ≤ 3 cm with total tumor diameter ≤ 8 cm) who achieved successful down-staging (DS) to Milan criteria had similar outcomes after liver transplantation (LT) compared with HCC initially meeting the Milan criteria. Nevertheless, little is known about the outcome of DS in patients with initial tumor burden exceeding the UCSF-DS criteria, defined as "all-comers" (AC). We compared the intention-to-treat (ITT) outcomes of DS in 74 patients in the AC group and 133 patients in the UCSF-DS group. Successful DS to Milan was observed in 64.8% of the AC group versus 84.2% of the UCSF-DS group (P < 0.001). The sum of tumor number and largest tumor diameter was significantly associated with successful DS (hazard ratio [HR] 0.87, P < 0.05). The cumulative probability of dropout within 1 year and 3 years was 53.5% and 80.0%, respectively, for AC versus 25.0% and 36.1%, respectively, for UCSF-DS (P < 0.0001). Factors predicting dropout included sum of tumor number and largest tumor diameter greater than 8 (HR 1.79, P = 0.049) and Child class B and C (HR 2.54, P = 0.001). The AC group also had a significantly lower liver transplant (LT) rate (13.5% versus 59.0%, P < 0.001). ITT survival at 1 year and 5 years was 77.4% and 21.1%, respectively, in AC versus 85.5% and 56.0%, respectively, in UCSF-DS (P < 0.001). Three of 10 patients in the AC group who underwent LT developed HCC recurrence. Conclusion: We observed a significantly lower LT probability and inferior ITT survival with DS in the AC group versus the UCSF-DS group. Our results suggest that an upper limit in tumor burden exists beyond which successful LT after DS becomes an unrealistic goal.
引用
- Sinha J, Mehta N, Dodge JL, et al. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol. Hepatology. 2019. PMID: 30779440. doi:10.1002/hep.30570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。